Developing new partners and advancing partnership businesses with existing partners
First written in FY2016. 19 of 21 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2022: 1 of 12 companies on the "Worse" side.
4 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for partners' clinical development remains unchanged. - FY2025RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for partners' clinical development remains unchanged. - FY2024-Q3AdvancedAnnual report
「For OTS167, which targets MELK (Maternal Embryonic Leucine zipper Kinase), a kinase important for maintaining cancer stem cells, the aim is to out-license it to a pharmaceutical company at its current stage of development, rather than complete the previously planned in-house Phase 1 clinical trial.」
The partnership and out-licensing policy now explicitly states that OTS167 will be out-licensed to a pharmaceutical company at its current development stage, rather than after completing an in-house Phase 1 clinical trial. - FY2023-Q3RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for partners' clinical development remains unchanged. - FY2023-Q1RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for partners' clinical development remains unchanged. - FY2022-Q3RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for partners' clinical development remains unchanged. - FY2022-Q1RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for partners' clinical development remains unchanged. - FY2021-Q3RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for partners' clinical development remains unchanged. - FY2021-Q2RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for partners' clinical development remains unchanged. - FY2021-Q1RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for partners' clinical development remains unchanged. - FY2020-Q3RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for clinical development remains unchanged. - FY2020-Q2RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for partners' clinical development remains unchanged. - FY2020-Q1RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for partners' clinical development remains unchanged. - FY2018RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing commercialization through the development of new partnerships, dialogue with existing partners, and support for partners' clinical development remains unchanged. - FY2018-Q3RestatedAnnual report
「Regarding the cancer-specific peptide vaccine, we have promoted strategic dialogue with partner pharmaceutical companies and strengthened support for and assistance with their clinical development activities.」
Dialogue with partner pharmaceutical companies and support for partner-led clinical development remain ongoing. - FY2018-Q2RestatedAnnual report
「Regarding the cancer-specific peptide vaccine, we have promoted strategic dialogue with partner pharmaceutical companies and strengthened support for and assistance with their clinical development activities.」
Dialogue with partner pharmaceutical companies and support for partner-led clinical development remain ongoing. - FY2017RestatedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
The policy of pursuing the launch of drug candidates through the development of new partnerships, dialogue with existing partners, and support for clinical development remains unchanged. - FY2017-Q3RestatedAnnual report
「Regarding the cancer-specific peptide vaccine, we have promoted strategic dialogue with partner pharmaceutical companies and strengthened support for and assistance with their clinical development activities.」
Dialogue with partner pharmaceutical companies and support for partner-led clinical development remain ongoing. - FY2017-Q2RestatedAnnual report
「Regarding the cancer-specific peptide vaccine, we have promoted strategic dialogue with partner pharmaceutical companies and strengthened support for and assistance with their clinical development activities.」
Dialogue with partner pharmaceutical companies and support for clinical development remain ongoing. - FY2017-Q1RestatedAnnual report
「Regarding the cancer-specific peptide vaccine, we have promoted strategic dialogue with partner pharmaceutical companies and strengthened support for and assistance with their clinical development activities.」
Measures to support partner-led clinical development remain in place. - FY2016First statedAnnual report
「We will continue to actively seek new partners, promote strategic dialogue with partner pharmaceutical companies, and strengthen our support for the clinical development conducted by partners, both alongside and behind the scenes, in order to advance partnership businesses reliably and expeditiously and bring our Group’s drug candidates to market as soon as possible.」
Licensing and joint development with pharmaceutical companies are positioned as key means of commercializing drug candidates.